Synthomer has spent years cutting Debt , selling businesses and shrinking its footprint, and in 2026 the effort is finally showing in the numbers — margins expanding, guidance upgraded and the shares up sharply. But high Leverage and negative first-half Cash Flow mean the polymer specialist’s recovery, while real, is not yet fully de-risked.

Introduction

For much of the past few years, Synthomer was a story about debt — too much of it, in a chemicals downturn. In 2026 the narrative is shifting. Margins are expanding, guidance has been upgraded and the shares have nearly doubled over the year, suggesting the low point may already be behind it. Yet leverage remains elevated and cash flow turned negative in the first half, so the turnaround is gaining traction without being complete.

Company overview

Synthomer is a London-listed specialty-chemicals company making polymers, latex, adhesives and coatings, organised into coatings and construction, adhesives, and a health-and-protection and performance-materials segment that includes materials for nitrile gloves. Based in Harlow, it has a supportive anchor Shareholder in Malaysia’s Kuala Lumpur Kepong. In early August 2026 the shares traded around 122p for a Market Capitalisation of roughly £200m, having risen about 97% over the prior year off a very low base. It pays no Dividend , prioritising debt reduction.

Latest developments

The past year has been about de-risking and simplification. In 2025 Synthomer relaxed its debt covenants amid weak conditions, sold its William Blythe inorganic-chemicals Business for £30m and targeted cost savings and role reductions. In early 2026 it addressed a looming 2027 debt Maturity , completing a refinancing by April without issuing new Equity , and its board stated it did not intend to raise fresh equity. In June it agreed to divest a loss-making acrylate-monomers business, and an AGM statement reported second-quarter trading ahead of expectations, helped partly by a non-recurring competitor Supply disruption that boosted glove-related volumes.

The first-half 2026 results in August confirmed the improving trend and upgraded guidance to slightly ahead of expectations. Revenue rose 5%, adjusted EBITDA climbed over 13% with margins expanding, and the company continued to shrink its Manufacturing footprint — from over 40 sites a few years ago toward a target below 25. The refinancing and portfolio simplification have removed the existential financing questions that dogged the stock, even as leverage remains a live issue.

Financial performance

The half-year numbers showed momentum. Revenue reached about £954m, up 5% at constant currency, and adjusted EBITDA rose to £96.7m, a 13% increase, with the Margin improving to around 10%. But net debt rose to £671m on a seasonal working-capital build, keeping covenant leverage near 4.9 times, and free cash flow was sharply negative in the half, though the company guided to positive full-year cash flow. Full-year 2025 revenue was about £1.74bn with adjusted EBITDA of £136.5m. No dividend is paid, with cash directed to deleveraging.

Industry outlook

The specialty-chemicals sector is emerging unevenly from a multi-year destocking cycle. Synthomer’s recent growth has drawn on intumescent coatings for data centres and infrastructure, energy-related Demand , Chinese adhesives expansion and a surge in glove-related volumes tied to a competitor’s supply disruption — the last of which the company flags as partly non-recurring. Against that, US coatings demand and oil-and-gas drilling activity have been soft, and Asian nitrile-latex overcapacity remains a structural feature, so the demand recovery is patchy rather than uniform.

Bull case

The bull case is a genuine Earnings inflection backed by self-help. Margins have expanded across the past two years, guidance was upgraded, and the refinancing was completed without dilution, removing a major overhang. Portfolio simplification — exiting loss-making and non-core businesses and cutting the site count sharply — is sharpening the mix toward higher-margin specialties, and a supportive anchor shareholder adds stability. Diversifying growth drivers, from data-centre coatings to medical adhesives, broaden the base.

Bear case and risks

The bear case is leverage and cash. Net debt rose in the first half to keep covenant leverage near 4.9 times, uncomfortably close to its ceilings, and free cash flow was significantly negative, leaving the full-year positive-cash-flow guidance to be proven. Part of the first-half Volume strength came from a competitor disruption the company itself calls non-recurring, raising Reversal risk, and continuing-operations revenue still fell in 2025. There is no dividend, and demand recovery remains uneven.

Key catalysts

Catalysts include completion of the acrylate-monomers divestment, progress toward the year-end leverage target, the next trading update and full-year results, whether the glove-related volume tailwind persists or reverses, and any signal on eventual dividend reinstatement — of which there is none yet.

Conclusion

Synthomer’s long, grinding turnaround is finally showing up where it matters: in margins, guidance and a re-rated share price, with the refinancing removing the worst of the financing risk. The evidence suggests the bottom has likely passed. But high leverage and negative first-half cash flow mean the recovery is not yet secure, and part of the recent strength may not last. The direction of travel is encouraging; the destination — a comfortably de-levered, cash-generative specialist — is not yet reached.

The share-price near-doubling reflects the market pricing out failure risk rather than pricing in a full recovery, which is a reasonable place for the stock to be. From here the burden of proof sits with cash generation: if the second half delivers the promised positive free cash flow and leverage starts to fall, the equity has further to go; if Working Capital and soft demand keep cash trapped, the covenant headroom question returns. It is a credible recovery play for investors comfortable with balance-sheet risk, and little else for those who are not.